Parsippany, NJ, USA – Daiichi Sankyo, Inc., a pharmaceutical company, announced that Glenn Gormley has been named corporate president and chairman of Daiichi Sankyo, Inc. [break]
Dr. Gormley will also continue in his existing roles as President, Daiichi Sankyo Pharma Development, Global Head of Research and Development and Senior Executive Officer of Daiichi Sankyo, Co. Ltd.
As head of global R&D, Dr. Gormley chairs the Executive Management decision body for R&D and oversees the four regional development organizations: Americas Region, EU/India Region, Japan Region and Asia Development Region. In his role as President of DSPD, Dr. Gormley is a board member of Daiichi Sankyo Incorporated. He was formerly Chief Executive Officer of Gemin X Pharmaceuticals, a North American oncology company.
Prior to Gemin X, Dr. Gormley held the position of Global Head of Clinical Development and Medical Affairs at Novartis. Before joining Novartis, Dr. Gormley served as Chief Medical Officer for AstraZeneca, where he continued his academic appointment as a member of the Clinical Faculty at New York University and served as a Trustee of the University of Delaware. Early in his career, Dr. Gormley held the position of VP of US clinical Development at Merck.
Dr. Gormley volunteers on a number of boards and committees, including the Board of Directors for the American Society of Clinical Pharmacology (ASCPT), the Board of Directors of the Biotechnology Industry Organization (BIO), the PhRMA Science and Regulatory Committee and is a member of the University of Delaware College of Health Sciences oversight committee.
Dr. Gormley received his M.D. and Ph.D. in Chemistry from the University of Chicago and received board certifications in Pediatrics from UCLA and Endocrinology from New York University. He completed his post doc fellowship in oncology from the Ben May Institute in Chicago and has been the recipient of several Mac Arthur fellowships. He has remained committed to the fields of clinical pharmacology and endocrinology and published many papers of original research.
In addition, Greg Barrett has been appointed as the new acting head of the Commercial Division of Daiichi Sankyo, Inc. in the U.S.
Mr. Barrett most recently held the position of Vice President, Marketing and Managed Markets, at Daiichi Sankyo, Inc. and has been with the company since the late 1990’s.
Daiichi Sankyo, Inc.’s former President and CEO, and head of its Commercial Division, John Gargiulo, has left the company effective October 3, 2013.
Mr. Gargiulo has been the Chief Executive Officer and President of Daiichi Sankyo, Inc. since April 4, 2011. Mr. Gargiulo served as Senior Vice President of Commercial Operations, where he oversaw U.S. Marketing, Supply Chain, Managed Markets and New Product Planning.
After joining the predecessor organization, Sankyo, in 1995, he was instrumental in advancing DSI from a joint venture with Parke - October 4, 2013, Parsippany, NJ, USA – Daiichi Sankyo, Inc., a pharmaceutical company, announced that Glenn Gormley has been named corporate president and chairman of Daiichi Sankyo, Inc.
Article continues below
]
Dr. Gormley will also continue in his existing roles as President, Daiichi Sankyo Pharma Development, Global Head of Research and Development and Senior Executive Officer of Daiichi Sankyo, Co. Ltd.
As head of global R&D, Dr. Gormley chairs the Executive Management decision body for R&D and oversees the four regional development organizations: Americas Region, EU/India Region, Japan Region and Asia Development Region. In his role as President of DSPD, Dr. Gormley is a board member of Daiichi Sankyo Incorporated. He was formerly Chief Executive Officer of Gemin X Pharmaceuticals, a North American oncology company.
Prior to Gemin X, Dr. Gormley held the position of Global Head of Clinical Development and Medical Affairs at Novartis. Before joining Novartis, Dr. Gormley served as Chief Medical Officer for AstraZeneca, where he continued his academic appointment as a member of the Clinical Faculty at New York University and served as a Trustee of the University of Delaware. Early in his career, Dr. Gormley held the position of VP of US clinical Development at Merck.
Dr. Gormley volunteers on a number of boards and committees, including the Board of Directors for the American Society of Clinical Pharmacology (ASCPT), the Board of Directors of the Biotechnology Industry Organization (BIO), the PhRMA Science and Regulatory Committee and is a member of the University of Delaware College of Health Sciences oversight committee.
Dr. Gormley received his M.D. and Ph.D. in Chemistry from the University of Chicago and received board certifications in Pediatrics from UCLA and Endocrinology from New York University. He completed his post doc fellowship in oncology from the Ben May Institute in Chicago and has been the recipient of several Mac Arthur fellowships. He has remained committed to the fields of clinical pharmacology and endocrinology and published many papers of original research.
In addition, Greg Barrett has been appointed as the new acting head of the Commercial Division of Daiichi Sankyo, Inc. in the U.S.
Mr. Barrett most recently held the position of Vice President, Marketing and Managed Markets, at Daiichi Sankyo, Inc. and has been with the company since the late 1990’s.
Daiichi Sankyo, Inc.’s former President and CEO, and head of its Commercial Division, John Gargiulo, has left the company effective October 3, 2013.
Mr. Gargiulo has been the Chief Executive Officer and President of Daiichi Sankyo, Inc. since April 4, 2011. Mr. Gargiulo served as Senior Vice President of Commercial Operations, where he oversaw U.S. Marketing, Supply Chain, Managed Markets and New Product Planning.
After joining the predecessor organization, Sankyo, in 1995, he was instrumental in advancing DSI from a joint venture with Parke-Davis to its current status as a Leader in hypertension therapy and with an emerging presence in thrombosis and oncology. ■